Blood pressure medication recall over cancer risk expanded for more losartan drugs




  • In Business
  • 2019-01-24 02:25:38Z
  • By USA TODAY
 

As part of a growing number of blood pressure drug recalls, Torrent Pharmaceuticals has expanded its recall of losartan medication over concerns it contains a carcinogen.

Torrent said six additional lots of losartan potassium and hydrochlorothiazide tablets contain trace amounts of the probable human carcinogen N-nitrosodiethylamine (NDEA), according to a notice shared Tuesday by the Food and Drug Administration.

The India-based pharmaceutical company has already recalled 10 lots of losartan potassium tablets in the past two months, and since July, more than a dozen other recalls have been issued for common blood pressure medications.

The recalls have been linked to two overseas factories that made the drugs' active ingredients, which the FDA has said it is investigating. The drugs have been found to contain either NDEA or N-Nitrosodimethylamine (NDMA).

Check your medication: Here's how to see if your blood pressure meds are recalled over possible cancer risk

Various versions of valsartan, losartan and irbesartan drugs have been part of the recalls. These medications are part of a large class called angiotensin II receptor blockers (ARBs), which lower blood pressure by widening or relaxing blood vessels.

However, not all ARBs contain NDMA or NDEA or are under recall, and alternative treatments or medications can be prescribed in consultation with physicians, the FDA says.

The agency is telling patients to continue taking their medication "as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment," the FDA said.

Q&A: Why do blood pressure medications keep getting recalled? Here's what to know.

Click here to find out if your medication is affected by the recent recalls, or visit the FDA website. The agency has updated lists for all three kinds of drugs affected by the recalls.

Contributing: Ken Alltucker, USA TODAY. Follow USA TODAY's Ryan Miller on Twitter: @RyanW_Miller

Alternatives: Blood pressure drug substitutes are available for patients affected by recalls, doctors say

This article originally appeared on USA TODAY: Blood pressure medication recall over cancer risk expanded for more losartan drugs

COMMENTS

More Related News

Young Blood Scam: FDA Warns Against Unproven Anti-Aging Transfusions
Young Blood Scam: FDA Warns Against Unproven Anti-Aging Transfusions

If thereported claims about those treatments sound too good to be true, that'sbecause they are, according to the FDA

Don't Buy Young People's Blood to Stop Aging, FDA Warns
Don't Buy Young People's Blood to Stop Aging, FDA Warns

Don't Buy Young People's Blood to Stop Aging, FDA Warns

Philippines revokes Sanofi
Philippines revokes Sanofi's product license for dengue vaccine

The Philippines has permanently halted the sale, distribution and marketing of Sanofi's dengue vaccine in the country after the French drug maker failed to meet the directives of regulators. Food and Drug Administration (FDA) Director General Nela Charade Puno said on Tuesday registration certificates for Dengvaxia products have been revoked because of Sanofi's "brazen defiance" of the agency's directives. The FDA said Sanofi failed to comply with post marketing authorization requirements as of December last year.

Baby Gripe Water sold at Dollar General recalled
Baby Gripe Water sold at Dollar General recalled

Kingston Pharma is voluntarily recalling all lots of DG Baby Gripe Water because it has "the presence of an undissolved ingredient, citrus flavonoid."

Merck Gets Priority Review for Keytruda Combo in Kidney Cancer
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer

Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business

facebook
Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.